Kidney Week

Abstract: TH-PO0632

Serum and Urinary V-Set and Immunoglobulin Domain-Containing 4 (VSIG4) Levels Associated with Rapid Kidney Function Decline in Patients with CKD

Session Information

• CKD: Clinical - Guidelines, Biomarkers, Progression, Procedures, Outcomes, and More
  October 22, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

• 2202 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

• Han, Sang Youb, Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea (the Republic of)

Sang Youb Han, MD, PhD

• Han, Seung hyun, Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea (the Republic of)

Seung hyun Han, MD

• Park, Seok ju, Inje University Busan Paik Hospital, Busan, Korea (the Republic of)

Seok ju Park, MD

Background

VSIG4 (CRIg) is a macrophage-associated complement receptor implicated in inflammation and fibrosis. We investigated whether serum and urinary VSIG4 levels are associated with rapid kidney function decline in chronic kidney disease.

Methods

We enrolled 84 patients with CKD (mean age 56.8 ± 14.2 years; 47.6% male), including diabetic kidney disease (n = 27), IgA nephropathy (n = 25), focal segmental glomerulosclerosis (n = 10), and other etiologies. Mean baseline estimated glomerular filtration rate (eGFR) was 81.7 ± 34.6 mL/min/1.73 m², and median urine protein-to-creatinine ratio was 1.21 (interquartile range [IQR], 0.42–3.48) g/g creatinine. Serum and urinary VSIG4 concentrations were measured by enzyme-linked immunosorbent assay. Urinary VSIG4 was normalized to urine creatinine. Kidney function decline was defined as the change in eGFR over two years. Rapid progressors were defined as patients with a decline in eGFR greater than 10 mL/min/1.73 m² over two years. Multivariable logistic regression models were constructed to evaluate the association between VSIG4 levels and rapid kidney function decline after adjustment for age, sex, baseline eGFR, and urine protein excretion.

Results

Among the 84 participants, 12 (14.3%) were classified as rapid progressors. Rapid progressors had significantly higher serum VSIG4 levels than non-rapid progressors (median 24.8 vs. 18.8 ng/mL, p = 0.0288; area under the receiver operating characteristic curve [AUC] = 0.699). Urinary VSIG4 normalized to creatinine was also higher in rapid progressors (median 47.1 vs. 16.1 pg/mg creatinine), with borderline significance (p = 0.065; AUC = 0.668).
In participants with preserved kidney function at baseline (eGFR ≧60 mL/min/1.73 m², n = 63), serum VSIG4 remained significantly higher in rapid progressors (20.6 vs. 15.0 ng/mL, p = 0.023; AUC = 0.740), whereas urinary VSIG4 levels showed a similar trend (37.6 vs. 15.5 pg/mg creatinine, p = 0.067; AUC = 0.693). In multivariable models adjusting for age, sex, baseline eGFR, and proteinuria, higher serum VSIG4 showed a consistent association with rapid kidney function decline.

Conclusion

Higher serum and urinary VSIG4 levels were associated with rapid kidney function decline in CKD. Serum VSIG4 may serve as a promising biomarker for accelerated CKD progression.

Funding

• Government Support – Non-U.S.